Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...

PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.